Answers are grounded in this paper and cite their sources.
Objective The rising global incidence of Pneumocystis jirovecii pneumonia (PJP) in HIV-negative populations, characterized by atypical presentation, rapid progression, and high mortality, poses a significant clinical challenge. This study aimed to summarize the clinical, diagnostic, and therapeutic profiles of HIV-negative PJP and identify independent prognostic factors to refine clinical management. Methods A retrospective multicenter analysis was conducted on 233 HIV-negative PJP patients from five tertiary hospitals (December 2019 – June 2025), stratified into survivors ( n = 135) and non-survivors ( n = 98). Baseline demographics, laboratory indices, imaging, diagnostic modalities, and treatments were compared. Univariate and multivariate logistic regression identified mortality risk factors. Results The cohort (167 males, 66 females; mean age 53.00 ± 18.25 years) had a median symptom-to-admission time of 5 days and median hospital stay of 18 days. Underlying diseases were present in 84.55%. Atypical symptoms were common; 66.09% had an oxygenation index <300 mmHg (median 217.03; IQR 109.72–325.70), and 28.33% were 1,3- β -D-glucan positive. Significant intergroup differences ( P < 0.05) were observed for several laboratory and physiological parameters, including platelet count (PLT), procalcitonin (PCT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), oxygenation index (OI), 1,3- β -D-glucan (BDG), and tachypnea (≥30/min). Imaging revealed ground-glass opacities, patchy shadows, and septal thickening; pleural effusion, consolidation, and nodules differed significantly between groups ( P < 0.05). Among 197 mNGS-tested patients, polymicrobial co-detection was common, with viral, bacterial, and fungal positivity rates of 69.04%, 38.07%, and 26.40%, respectively; EBV, H. parainfluenzae , and P. aeruginosa were more frequently co-detected in non-survivors ( P < 0.05). Treatments, including antivirals, immunoglobulins, and mechanical ventilation, differed significantly ( P < 0.05). Multivariate analysis identified smoking history (OR = 1.818, 95% CI: 1.043–3.170, P = 0.035), shock (OR = 2.787, 95% CI: 1.453–5.348, P = 0.002), underlying pulmonary disease (OR = 3.488, 95% CI: 1.864–6.524, P < 0.001), positive BALF EBV nucleic acid (OR = 6.635, 95% CI: 1.281–34.362, P = 0.024), AST (OR = 1.033, 95% CI: 1.025–1.042, P < 0.001), and tachypnea ≥30/min (OR = 2.520, 95% CI: 1.286–4.938, P = 0.007) as independent mortality risk factors. The multivariable model achieved an AUC of 0.857 from ROC analysis. Conclusion HIV-negative PJP presents with nonspecific features and frequent polymicrobial co-detection of pathogens, contributing to high 28-day all-cause mortality. BALF mNGS can simultaneously detect Pneumocystis jirovecii and polymicrobial co-pathogens in immunocompromised patients, yet this retrospective cohort was not designed as a diagnostic accuracy trial; mNGS can only act as an auxiliary pathogen detection tool rather than a universal early screening test for suspected PJP. Close monitoring of these identified exploratory risk factors and timely targeted interventions are crucial for improving prognosis. Further external-cohort validations are warranted before applying these markers for clinical risk stratification.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: